2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1248

Revisit an Old Question: Should Glucose-6-Phosphate Dehydrogenase Level be Checked in Patients with Rheumatic Diseases Prior to Initiating Certain Drugs?
Abstract Number: 354

Rheumatic Complications of Immune Checkpoint Inhibitor Therapy: A Single Center Experience
Abstract Number: 2256

Rheumatic Diseases Associated with Neuromyelitis Optica Spectrum Disorders (NMOSD): Prevalence, Clinical, Laboratory and Imaging Characteristics
Abstract Number: 351

Rheumatic Immune-Related Adverse Events in Patients on ANTI-PD-1 Inhibitors: Fasciitis with Myositis Syndrome As a New Rheumatic Complication of Immunotherapy
Abstract Number: 1914

Rheumatic Syndromes Associated with Immune-Checkpoint Inhibitors: A Single-Center Cohort of 61 Patients
Abstract Number: 79

Rheumatoid Arthritis (RA)-Associated Autoantibodies Are Present in the Periodontal Exudate of Patients with and without RA
Abstract Number: 1467

Rheumatoid Arthritis Activity Monitoring and Multiplex Biomarker Verification By Tageted Proteomics
Abstract Number: 1825

Rheumatoid Arthritis Associated Haploinsufficiency in PTPN2 Enhances Severity of IL-17 Mediated Autoimmune Arthritis
Abstract Number: 884

Rheumatoid Arthritis Disease Activity Predicting Incident Clinically-Apparent Interstitial Lung Disease: A Prospective Cohort Study
Abstract Number: 2332

Rheumatoid Arthritis Effect´s on Bone Mass and Muscle
Abstract Number: 920

Rheumatoid Arthritis Patient-Specific Therapeutic Target Identification Using Integrative Epigenetic Profiling
Abstract Number: 484

Rheumatoid Arthritis Patients Have Lower Preoperative Expectations but Greater Clinical Improvement after Total Knee Arthroplasty Compared to Osteoarthritis Patients
Abstract Number: 227

Rheumatoid Arthritis Patients Treated with Abatacept, Rituximab and Tocilizumab in Denmark and Sweden: Risk of Serious Infections
Abstract Number: 87

Rheumatoid Arthritis Patients with Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity
Abstract Number: 1015

Rheumatoid Arthritis Peripheral CD14+ Monocytes Are Hyper-Inflammatory, Hyper-Glycolytic and Retain a Memory Bias Toward M1 Macrophages

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].